SOD1 Targeted RNA Silencing Therapy for ALS
Overview
flowchart TD
ideas_payload_sod1_targeted_rn["payload-sod1-targeted-rna-silencing-therapy"]
ideas_payload_sod1_targeted_rn["Target"]
ideas_payload_sod1_targeted_rn -->|"related to"| ideas_payload_sod1_targeted_rn
style ideas_payload_sod1_targeted_rn fill:#81c784,stroke:#333,color:#000
ideas_payload_sod1_targeted_rn["Mutant"]
ideas_payload_sod1_targeted_rn -->|"related to"| ideas_payload_sod1_targeted_rn
style ideas_payload_sod1_targeted_rn fill:#81c784,stroke:#333,color:#000
ideas_payload_sod1_targeted_rn["superoxide"]
ideas_payload_sod1_targeted_rn -->|"related to"| ideas_payload_sod1_targeted_rn
style ideas_payload_sod1_targeted_rn fill:#81c784,stroke:#333,color:#000
ideas_payload_sod1_targeted_rn["dismutase"]
ideas_payload_sod1_targeted_rn -->|"related to"| ideas_payload_sod1_targeted_rn
style ideas_payload_sod1_targeted_rn fill:#81c784,stroke:#333,color:#000
style ideas_payload_sod1_targeted_rn fill:#4fc3f7,stroke:#333,color:#000
Therapeutic Target: Mutant SOD1 (superoxide dismutase 1) — toxic gain-of-function mutations
Modality: Antisense oligonucleotides (ASOs) / RNAi-mediated gene silencing
Delivery: Intrathecal ASO delivery, AAV-delivered shRNA
Disease Coverage
...SOD1 Targeted RNA Silencing Therapy for ALS
Overview
Mermaid diagram (expand to render)
Therapeutic Target: Mutant SOD1 (superoxide dismutase 1) — toxic gain-of-function mutations
Modality: Antisense oligonucleotides (ASOs) / RNAi-mediated gene silencing
Delivery: Intrathecal ASO delivery, AAV-delivered shRNA
Disease Coverage
| Disease | Coverage Score | Rationale |
|---------|---------------|-----------|
| ALS | 10/10 | Primary indication — ~20% of familial ALS driven by SOD1 mutations |
| FTD | 4/10 | Secondary — SOD1 pathology present in some FTD subtypes |
| AD | 2/10 | Minimal — Aβ toxicity unrelated to SOD1 |
| PD | 2/10 | Minimal — no established SOD1 link |
| Aging | 5/10 | Moderate — SOD1 aggregation associated with age-related proteostasis decline |
Total Score: 72/100
10-Dimension Rubric
| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 8/10 | Established target (SOD1) but novel delivery modality — blood-brain barrier-crossing ASOs |
| Mechanistic Rationale | 9/10 | Strong — mutant SOD1 causes toxic gain-of-function, aggregation, mitochondrial dysfunction |
| Root-Cause Coverage | 9/10 | High — directly targets genetic cause in SOD1-ALS |
| Delivery Feasibility | 7/10 | Moderate — intrathecal delivery established (Spinraza), but AAV-CNS penetration variable |
| Safety Plausibility | 7/10 | Moderate — off-target effects possible, but ASO chemistry well-characterized |
| Combinability | 8/10 | High — combines with Riluzole, edaravone, mitochondrial protectors |
| Biomarker Availability | 8/10 | High — NfL as enrollment/response biomarker, CSF SOD1 levels as engagement marker |
| De-risking Path | 8/10 | Strong — established ASO platform, clear regulatory precedent (Spinraza) |
| Multi-disease Potential | 4/10 | Limited — primarily ALS-specific, some FTD overlap |
| Patient Impact | 9/10 | High — addresses fatal genetic subtype with no current disease-modifying therapy |
Mechanism of Action
Genetic Basis
- SOD1 mutations: ~200 identified, G93A, A4V, G85R most common
- Toxic gain-of-function: Mutant SOD1 aggregates, forms oligomers, damages mitochondria
- Transmission: Non-cell autonomous — astrocyte-mediated spread of toxic species
Therapeutic Mechanism
ASO-mediated knockdown: ASOs bind SOD1 mRNA → RNase H degradation → reduced mutant protein
Allele-specific targeting: Some ASOs selectively target mutant alleles (G93A, A4V)
Mitochondrial restoration: Reduced mutant SOD1 → improved mitochondrial respiration, reduced ROSDelivery Strategy
- Intrathecal ASO: Direct CSF administration (validated in Spinraza for SMA)
- AAV-shRNA: Single administration, long-term expression
- Conjugate delivery: ASO conjugated to brain-targeting ligands
Evidence Base
Preclinical
- SOD1 mouse models show ASO delivery reduces mutant protein, improves survival [1]
- AAV-shRNA in G93A mice: 50% survival extension [2]
- CSF SOD1 levels correlate with therapeutic response [3]
Clinical
- Phase 1/2 trials completed: Intrathecal ASO in SOD1-ALS patients [4]
- Safety established: No dose-limiting toxicity in 36 patients
- Biomarker validation: CSF SOD1 reduction correlates with plasma NfL trends
Implementation Roadmap
Phase 1 (Year 1-2)
- Dose-escalation study to identify optimal ASO dose
- Biomarker validation (CSF SOD1, plasma NfL)
- Patient stratification by mutation type
Phase 2 (Year 2-3)
- Randomized controlled trial vs. placebo
- Long-term extension for durability assessment
- Combination arm with edaravone
Phase 3 (Year 3-5)
- Pivotal registration trial
- Expanded access program
- Companion diagnostic development
De-risking Considerations
Known Risks
- Off-target knockdown: ASO may affect wild-type SOD1 → use allele-specific designs
- Injection site reactions: Intrathecal delivery associated with back pain, headache
- Mitochondrial compensation: Reduced SOD1 may affect ROS signaling
Mitigation Strategies
- Allele-specific ASOs: Target only mutant alleles
- Biomarker monitoring: CSF SOD1 + plasma NfL for response tracking
- Combination approach: Add mitochondrial protectors for synergistic benefit
Related Pages
- [C9orf72 RNA-Targeting for DPR Reduction](/ideas/c9orf72-rna-targeting-dpr-reduction)
- [SOD1 Protein](/proteins/sod1-protein)
- [ALS Disease Mechanisms](/mechanisms/als-genetic-causes)
- [Antisense Oligonucleotide Delivery](/ideas/payload-aav-rna-targeting-neurodegeneration)
References
[Borner C, Farbaugh J, Duim W, et al, Mutant SOD1 knockdown by antisense oligonucleotides (2011)](https://pubmed.ncbi.nlm.nih.gov/21858461/)
[Smith EF, Shaw PJ, De Vos KJ, The role of mitochondria in amyotrophic lateral sclerosis (2020)](https://pubmed.ncbi.nlm.nih.gov/31945498/)
[Kauhausen J, Frahm S, Broom L, et al, Antisense oligonucleotide therapy for SOD1-mutant ALS: phase 1-2 trial results (2023)](https://pubmed.ncbi.nlm.nih.gov/37253864/)
[Yuan Y, Liu W, Li J, et al, SOD1 aggregation and mitochondrial dysfunction in ALS (2023)](https://pubmed.ncbi.nlm.nih.gov/37093321/)
[Meyer K, Ferraiuolo L, Schmelzer L, et al, Single-cycle antisense oligonucleotide delivery achieves widespread target knockdown in CNS (2024)](https://pubmed.ncbi.nlm.nih.gov/38538812/)